

Programme Schedule

Sunday September 7, 2014

- 16:15 Opening Ceremony**
- 16:35 Portugal: the Right Place to build Partnerships in Health**
Dr Joaquim CUNHA
(HEALTH CLUSTER PORTUGAL, Maia, Portugal)
- 16:50 Partnership between Public and Private Sources: Pharma and IMI Perspective**
Dr Paul Peter TAK
(EFPIA, Brentford, United Kingdom)
- 17:10 EFMC Award Ceremony**
- 17:35 The Nauta Award for Pharmacochemistry
Pursuing Compound Quality**
Dr Paul LEESON
(GLAXOSMITHKLINE, Nuneaton, United Kingdom)
- 18:20 High Resolution Mass Spectrometry in Clinical Proteomics**
Prof. Dr Matthias MANN
(MAX PLANCK INSTITUTE OF BIOCHEMISTRY, Martinsried, Germany)
- 19:10 Welcome Reception**

Programme Schedule

Monday September 8, 2014

- 08:30 The UCB-Ehrlich Award for Excellence in Medicinal Chemistry
Small Molecule Control Of Intracellular Protein Levels**
Prof. Craig CREWS
(YALE UNIVERSITY, New Haven, CT, United States)
- 09:15 The Prous Institute-Overton and Meyer Award for New Technologies i Drug Discovery
Thermodynamics Assisted Drug Discovery**
Dr György G. FERENCZY (HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)
Prof. György KESERU (HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)
- 10:00 Exhibition & Coffee**

Session 1.1 Inflammation: the Common Link in Multifactorial Disorders?

- 10:30 Session Chair**
Prof. Angeliki KOUROUNAKIS
(UNIVERSITY OF ATHENS, Athens, Greece)
- 10:35 Inflammation, Obesity and Metabolic Disease**
Dr Ajay CHAWLA
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)
- 11:15 CB2 Agonists Protect from Inflammation Related Kidney Damage and Fibrosis**
Dr Uwe GREETHER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)
- 11:35 The Discovery of APD334, a Selective S1P1 Functional Antagonist**
Dr Robert JONES
(ARENA PHARM, SAN DIEGO, United States)
- 11:55 Discovery of Small Molecule Ror? Modulators for the Treatment of Autoimmune Diseases**
Dr Frank NARJES
(ASTRAZENECA, Gothenburg, Sweden)

Session 1.2 Computational Approaches To Guide Medicinal Chemistry

- 10:30 Session Chair**
Prof. Helmut GRUBMÜLLER
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)
- 10:35 Mechanoenzymatics of Biomolecular Machines: Free Energies, Dynamics, Function**
Prof. Helmut GRUBMÜLLER
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)
- 11:15 Efficient Determination Of Protein-Ligand Standard Binding Free Energies And Permeabilities With A
Computational Microcalorimeter**
Dr Chris CHIPOT
(UNIVERSITY OF ILLINOIS, Urbana, United States)
- 11:35 Binding Affinity Prediction from Molecular Simulation – Soon a Standard Method in Structure-Based Drug
Design?**
Dr Clara CHRIST
(BAYER, Berlin, Germany)
- 11:55 P-Glycoprotein/Membrane Role on Multidrug Resistance: Insights from In Silico Studies**
Mr Ricardo FERREIRA
(FACULTY OF PHARMACY, UNIVERSITY OF LISBON, Lisbon, Portugal)

Session 1.3 Organic Synthesis that Changed Medicinal Chemistry

- 10:30 Session Chair**
Dr Morten JORGENSEN
(H. LUNDBECK A/S, Valby, Denmark)
- 10:35 Recent Advances In Asymmetric Catalysis**

Programme Schedule

Prof. Erick M. CARREIRA
(ETH ZÜRICH, Zürich, Switzerland)

11:15 New Stereoselective Organocatalytic Reactions for the Synthesis of Isoquinoline Alkaloids

Prof. Pier Giorgio COZZI
(UNIVERSITY OF BOLOGNA, Bologna, Italy)

11:35 Metalation of Polyfunctional Heterocyclic Compounds: Applications in Agrochemistry

Dr Marc MOSRIN
(BAYER CROPSOURCE AG, Frankfurt am Main, Germany)

11:55 Development of Novel Building Blocks to Accelerate Drug Discovery

Dr Pavel MYKHAILIUK
(ENAMINE, Kyiv, Ukraine)

12:15 Exhibition & Lunch

Session 2.4 Combating Antibiotic Resistance

13:15 Session Chair

Prof. Ada YONATH
(WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel)

13:20 Aminoglycoside Mechanisms of Action, Resistance and Toxicity – Prospects for Antibiotic Drug Development

Prof. Erik BOETTGER
(UNIVERSITY OF ZÜRICH, Zürich, Switzerland)

14:00 Visualising Novel Macrolide Antibiotics Bound to Their Ribosomal Target

Prof. Stephen DOUTHWAITE
(UNIVERSITY OF SOUTHERN DENMARK, Odense, Denmark)

14:20 The Ribosome as a Drug Target: Insights from Structural Investigations - Towards Rational Drug Design

Dr Moran SHALEV-BENAMI
(WEIZMANN INSTITUTE, Rehovot, Israel)

14:40 Antagonists of the Pseudomonas Quinolone Signal Receptor (PQSR) as Promising Anti-Virulence Agents

Dr Martin EMPTING
(HELMHOLTZ-INSTITUTE F. PHARMACEUTICAL RESEARCH SAARLAND, Saarbrücken, Germany)

Session 2.5 Taming Natural Products: Novel Natural Products, Complex Synthesis, Mutasynthesis

13:15 Session Chair

Prof. Anake KIJJOA
(UNIVERSITY OF PORTO, Porto, Portugal)

13:20 Natural Products as Driving Force for Innovation in Pharmaceutical Research and Development

Dr Esther SCHMITT
(NOVARTIS, Basel, Switzerland)

14:00 Sponging Off Nature for New Drug Leads

Prof. Raymond ANDERSEN
(UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada)

14:20 Bioactive Secondary Metabolites From The Soil And Marine-Derived Fungi Of The Genus Neosartorya

Prof. Anake KIJJOA
(UNIVERSITY OF PORTO, Porto, Portugal)

14:40 From Malaysian Biodiversity to the Total Synthesis of Dual Inhibitors of BCL-XL and MCL-1 Anti-Apoptotic Protein

Dr Fanny ROUSSE
(ICSN - CNRS, Gif sur Yvette, France)

Session 2.6 Mechanism-Based Prediction of Drug-Induced Liver Injury (Eufeps Session)

13:15 Session Chair

Prof. Nico VERMEULEN
(VU UNIVERSITY, Amsterdam, The Netherlands)

13:20 Mechanism-Based Prediction of Drug-Induced Liver Injury

Programme Schedule

Dr Christopher GOLDRING
(UNIVERSITY OF LIVERPOOL, Liverpool, United Kingdom)

14:00 Strategies to Identify and Manage the Risks of Chemically Reactive Drug Metabolites

Prof. Nico VERMEULEN
(VU UNIVERSITY, Amsterdam, The Netherlands)

14:20 Being More Certain About Uncertainty In Computational Toxicology Modeling

Dr Scott BOYER
(KAROLINSKA INSTITUTET, Barcelona, Spain)

14:40 Covalent Modification of Histones by Nevirapine - A Plausible Pathway to Nevirapine-Induced Cancers?

Dr Alexandra ANTUNES
(INSTITUTO SUPERIOR TÉCNICO, Lisbon, Portugal)

15:00 Exhibition & Coffee

15:30 MedChemComm Prize Winner : Phage Selection Of Bicyclic Peptides For Therapeutic Application

Prof. Christian HEINIS
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

Session 3.7 EFMC Session

15:55 Session Chair

Dr Phil JONES
(UNIVERSITY OF DUNDEE, Glasgow, United Kingdom)

16:00 The Open Phacts Discovery Platform - Semantic Data Integration For Medicinal Chemists

Prof. Gerhard ECKER
(UNIVERSITY OF VIENNA, Vienna, Austria)

16:30 European Lead Factory - Game Changing For Innovative Medicines

Dr Dimitrios TZALIS
(TAROS CHEMICALS, Dortmund, Germany)

17:00 Funding Opportunities with the Innovative Medicines Initiative 2

Dr Colm CARROLL
(INNOVATIVE MEDICINES INITIATIVE, Brussels, Belgium)

17:30 Poster Session I and Networking

19:30 End of the day

20:30 Concert (free of charge, but subject to registration)

Programme Schedule

Tuesday September 9, 2014

- 08:30 Prize Ceremony**
- 08:35 EFMC Prize for a Young Medicinal Chemist in Industry**
Design, Synthesis and Properties of Potent Inhibitors of Pseudomonas Aeruginosa Deacetylase LpxC
Dr Grazia PIZZI
(NOVARTIS PHARMA, Basel, Switzerland)
- 08:55 EFMC Prize for a Young Medicinal Chemist in Academia**
Inhibitors and Substrates of the Human Lysine Deacetylase Enzymes
Prof. Christian A. OLSEN
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)
- 09:15 Plenary Lecture**
Dr Sabine HADIDA
(VERTEX PHARMACEUTICALS, San Diego, United States)
- 10:00 Exhibition & Coffee**

Session 4.8 Applications of Positron Emission Tomography in Drug Discovery (ACS Session I)

- 10:30 Session Chair**
Dr Sam BONACORSI
(BRISTOL-MYERS SQUIBB, Princeton, United States)
- 10:35 PET Imaging: Synthesis of Radiopharmaceuticals and their Application in Personalized Medicine and Drug Discovery**
Dr Peter J.H. SCOTT
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)
- 11:15 A Rational Approach to the Development of Radioligands and PET Ligands for Drug Development**
Dr Chad ELMORE
(ASTRAZENECA PHARMACEUTICALS, Mölndal, Sweden)
- 11:35 Design, Synthesis and Development of Lysophosphatidic Acid Receptor 1 (LPA1) PET Radioligands for Lung Receptor Occupancy Imaging**
Dr Sam BONACORSI
(BRISTOL-MYERS SQUIBB, Princeton, United States)
- 11:55 Quantitative Imaging of Mglu5 Allosteric Binding Site and its Occupancy by Positron Emission Tomography with The Novel Fluorine-18 Labelled Probe [18f]Pss232**
Dr Stefanie KRAMER
(ETH ZÜRICH, Zürich, Switzerland)

Session 4.9 Decoding Disease: Liganding and Drugging Bromodomain Epigenetic Readers

- 10:30 Session Chair**
Prof. Stuart CONWAY
(UNIVERSITY OF OXFORD, Los Angeles, United States)
- 10:35 BETting on Bromodomains: Developing Inhibitors of the Bromodomain-Acetyl-Lysine Interaction**
Prof. Stuart CONWAY
(UNIVERSITY OF OXFORD, Los Angeles, United States)
- 11:15 A First In Class Chemical Probe For Family VIII Bromodomains**
Dr Dafydd OWEN
(PFIZER, Cambridge, United States)
- 11:35 Epigenetic Drug Discovery: Small Molecule Inhibitors of Class IV Bromodomain Proteins**
Prof. Paul FISH
(UCL SCHOOL OF PHARMACY, London, United Kingdom)

Programme Schedule

11:55 Interrogation the Bromodomain Family through Chemical Biology

Dr Steve BELLON
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

Session 4.10 Organic Synthesis: New Developments (EuChemS Session)

10:30 Session Chair

Prof. Péter MÁTYUS (SEMMELWEIS UNIVERSITY, Budapest, Hungary)
(THERMO FISHER SCIENTIFIC)

10:35 Experiences with Natural Product Total Synthesis

Prof. Alois FÜRSTNER
(MAX PLANCK INSTITUT FÜR KOHLENFORSCHUNG, Muelheim an der Ruhr, Germany)

11:15 New Synthetic Routes of Nitrogen and Oxygen Heterocycles and Related Compounds

Prof. Artur M.S. SILVA
(UNIVERSITY OF AVEIRO, Aveiro, Portugal)

11:35 Fast and Safe Synthesis of Pharmaceutically Relevant Molecules

Prof. Thomas WIRTH
(UNIVERSITY OF CARDIFF, Cardiff, United Kingdom)

11:55 Metal Assisted Synthetic Approaches to Heterocyclic Small Molecules for the Treatment of Cardiovascular Diseases

Prof. Marko D. MIHOVILOVIC
(VIENNA UNIVERSITY OF TECHNOLOGY, Vienna, Austria)

12:15 Exhibition & Lunch

Session 5.11 Oncology: Kinases and Beyond

13:15 Session Chair

Dr Mario VARASI
(EUROPEAN INSTITUTE OF ONCOLOGY, Milano, Italy)

13:20 Therapeutic Opportunities Offered by the Excessive Lactate Production in Cancer

Prof. Filippo MINUTOLO
(UNIVERSITY OF PISA, Pisa, Italy)

14:00 Novel Anti-Cancer Treatment Targeting Vps34

Dr Jessica MARTINSSON
(SPRINT BIOSCIENCE, Stockholm, Sweden)

14:20 Exploiting Tumor Metabolic Vulnerabilities with Novel OxPhos Inhibitors

Dr Maria Emilia DI FRANCESCO
(UTMD ANDERSON CANCER CENTER, Houston, United States)

14:40 Discovery and Characterization of A-366, a Novel, Potent and Highly Selective Inhibitor of Histone Methyltransferase G9a

Dr Michael MICHAELIDES
(ABBVIE, North Chicago, United States)

Session 5.12 Recent Advances in Anti-infective Agents (AFMC Session)

13:15 Session Chair

Dr Ming-Hua HSU
(NATIONAL TSING HUA UNIVERSITY, Hsinchu, Taiwan)

13:20 Development of New Anti-Infective Agents and a Novel Delivery Strategy

Prof. Reuben JIH-RU HWU
(NATIONAL TSING HUA UNIVERSITY, Hsinchu, Taiwan)

14:00 Synthesis of Anti-infective Cyclic Natural Products and Natural Product-like Compounds

Prof. Han-Young KANG
(CHUNGBUK NATIONAL UNIVERSITY, Cheongju, Korea, South)

14:20 Novel Boron-containing Anti-infective Agents

Programme Schedule

Dr Jacob PLATTNER
(ANACOR PHARMACEUTICALS, Palo Alto, United States)

14:40 Lectins as Targets in Antiadhesion Therapy - Example of DC-SIGN And FimH Antagonists

Prof. Marko ANDERLUH
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)

Session 5.13 New Strategies for Lead Generation

13:15 Session Chair

(THERMO FISHER SCIENTIFIC)

13:20 Integration of New Chemical Diversity and Design Approaches in Lead Generation

Dr Timothy GRESE
(ELI LILLY AND COMPANY, Indianapolis, United States)

14:00 The Impact of Polypharmacology on Lead Generation

Prof. Jordi MESTRES
(IMIM AND UNIVERSITY POMPEU FABRA, Girona, Spain)

14:20 Starting Small, Thinking Big: The Application of Fragment Based Drug Discovery to Lead Generation

Dr Steve WOODHEAD
(TAKEDA CALIFORNIA, San Diego, United States)

14:40 Discovery of the First and Only Small Molecule IL-17 Blockers

Dr Nils HANSEN
(VIPERGEN, Copenhagen, Denmark)

15:00 Exhibition & Coffee

15:30 Medicinal Chemistry Experts in Pharma are Helping us to Generate Freely Available Novel Probes in Order to Facilitate Target Discovery

Prof. Chas BOUNTRA
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

16:30 Poster Session II and Networking

18:30 End of the day

Programme Schedule

Wednesday September 10, 2014

- 08:30 IUPAC Richter Prize Lecture
Medicinal Chemistry, Quo Vadis? - The Changing Climate In R&D**
Dr Helmut BUSCHMANN
(PHARMA CONSULTING AACHEN, Aachen, Germany)
- 09:15 Innovation Through Chemistry at the Interfaces of the Scientific Disciplines**
Dr Martin MISSBACH
(NOVARTIS, Basel, Switzerland)
- 10:00 Exhibition & Coffee**

Session 6.14 New Chemical Entities: Beyond Small Molecules

- 10:30 Session Chair**
Prof. Stan VAN BOECKEL
(LEIDEN INSTITUTE OF CHEMISTRY, Leiden, The Netherlands)
- 10:35 Cyclic Peptides from the nature to the synthetic ones**
Prof. Fernando ALBERICIO
(INSTITUTE FOR RESEARCH IN BIOMEDICINE, Durban , South Africa)
- 11:15 Successful Drug Discovery And Development Case Studies Of Protein Epitope Mimetics**
Dr Daniel OBRECHT
(POLYPHOR, Allschwil, Switzerland)
- 11:35 Cell-Permeable Peptide Therapeutics to Effectively Access Intracellular Targets in Cancer Stem Cells**
Dr Jörg VOLLMER
(NEXIGEN, Cologne, Germany)
- 11:55 Novel Inhibitors of Alzheimer's Associated Beta-Secretase-Clusters of Heparan Sulfate**
Dr Olga ZUBKOVA
(VICTORIA UNIVERSITY OF WELLINGTON, Lower Hutt , New Zealand)

Session 6.15 Novel Agents for the Treatment of C. Difficile (ACS Session II)

- 10:30 Session Chair**
Prof. Steven FIRESTINE
(WAYNE STATE UNIVERSITY, Detroit, United States)
- 10:35 Discovery and Development of Surotomycin for the Treatment of C. difficile**
Dr Jared SILVERMAN
(CUBIST PHARMACEUTICALS, Lexington, United States)
- 11:15 Invited Lecture**
Dr Terry BOWLIN
(MICROBIOTIX, Worcester, United States)
- 11:35 Targeting Spore Germination to Prevent Clostridium Difficile Infections**
Dr Ernesto ABEL-SANTOS
(UNIVERSITY OF NEVADA, LAS VEGAS, Nevada, Las Vegas, United States)
- 11:55 Cadazolid: A New Antibiotic in Development for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)**
Dr Philippe PANCHAUD
(ACTELION PHARMACEUTICALS LTD, Allschwil, Switzerland)

Session 6.16 Kinetic and Thermodynamic Aspects of Ligand Binding

- 10:30 Session Chair**
Prof. György KESERU
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)
- 10:35 Exploring the Dynamics of Ligand-Protein Interactions using SPR Biosensors**

Programme Schedule

Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden)

- 11:15 Breaking The Equilibrium Dissociation Constant Into Fragments: The Use Of Binding Kinetics And Thermodynamics In The Development Of Selective Ligands.**

Prof. Iwan DE ESCH
(VU AMSTERDAM, Amsterdam, The Netherlands)

- 11:35 Medicinal Chemistry Optimisation Of Binding Kinetics**

Prof. Mike WARING
(ASTRAZENECA, Newcastle upon Tyne, United Kingdom)

- 11:55 CRTH2: Can Residence Time Help?**

Dr Elena GOMEZ
(ALMIRALL, BARCELONA, Spain)

- 12:15 Exhibition & Lunch**

Session 7.17 Recent Highlights in Medicinal Chemistry

- 13:15 Session Chair**

Prof. Carlos MONTANARI
(UNIVERSITY OF SAO PAULO, Sao Paulo, Brazil)

- 13:20 Cebranopadol, a Novel, Potent Analgesic**

Dr Henning STEINHAGEN
(GRÜNENTHAL, Verona, Italy)

- 13:40 Discovery of BAY 1002670 - A Highly Potent and Selective Progesterone Receptor Modulator for Gynecological Therapies**

Dr Wolfgang SCHWEDE
(BAYER, Berlin, Germany)

- 14:00 Design, Synthesis and Biological Evaluation of Potent and Selective Class IIA Histone Deacetylase Inhibitors as a Potential Therapy for Huntington's Disease**

Dr Christopher LUCKHURST
(BIOFOCUS, Saffron Walden, United Kingdom)

- 14:20 Structure-Guided Design of Potent, Selective, Orally Bioavailable Tankyrase Inhibitors**

Dr Erin DIMAURO
(AMGEN, Cambridge, United States)

- 14:40 Novel Potent Inhibitors of the Histone Demethylase KDM1A**

Dr Paola VIANELLO
(EUROPEAN INSTITUTE OF ONCOLOGY, Milan, Italy)

Session 7.18 Hot Topics in Ion Channels

- 13:15 Session Chair**

Prof. Brian COX
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Brighton, United Kingdom)

- 13:20 An Introduction To Ion Channels As Drug Targets**

Prof. Morten GRUNNET
(LUNDBECK, Valby, Denmark)

- 14:00 CNV1014802, a Novel Nav1.7 Selective State-Dependent Sodium Channel Blocker for the Treatment of Chronic Pain: From Discovery to Phase 2 Clinical Study**

Dr Gerard GIBLIN
(CONVERGENCE PHARMACEUTICALS, Cambridge, United Kingdom)

- 14:20 Pain-relieving Peptides Targeting Acid-Sensing Ion Channels**

Dr Eric LINGUEGLIA
(CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France)

- 14:40 Discovery of Ivacaftor (Vx-770), a Cftr Potentiator for the Treatment of Cystic Fibrosis in G551d Patients**

Dr Sabine HADIDA
(VERTEX PHARMACEUTICALS, San Diego, United States)

Session 7.19 Allosteric Modulators for CNS Diseases

Programme Schedule

13:15 Session Chair

Dr Wolfgang FROESTL
(AC IMMUNE, Lausanne, Switzerland)

13:20 Functional and Structural Insights into GPCR Allostery

Prof. Arthur CHRISTOPOULOS
(MONASH UNIVERSITY, Parkville, Australia)

14:00 Discovery of the mGlu5 Negative Allosteric Modulator RO4917523

Dr Georg JAESCHKE
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

14:20 Allosteric Protein Kinases Inhibitors for Neurodegenerative Diseases Therapies

Prof. Ana MARTINEZ
(INSTITUTO DE QUIMICA MEDICA-CSIC, Madrid, Spain)

14:40 Antibodies as Tools to Enable Small Molecule Drug Discovery

Dr Marta WESTWOOD
(UCB, Slough, United Kingdom)

15:00 Excursions

20:00 Banquet

Programme Schedule

Thursday September 11, 2014

Session 8.20 GPCR Structural Biology: New Therapeutic Opportunities?

08:30 Session Chair

Prof. Jan STEYAERT
(VUB, Brussels, Belgium)

08:35 High End Design for GPCRs: Combining Protein Structure, Biophysical Data and Computational Water Network Energies

Dr. Jonathan MASON
(HEPTARES THERAPEUTICS, Cambridge, United Kingdom)

09:15 Nanobody-Enabled Fragment Screening On Active-State Constrained GPCRs

Prof. Jan STEYAERT
(VUB, Brussels, Belgium)

09:35 Covalent Agonists Facilitating Crystallisation of GPCRs

Prof. Peter GMEINER
(FRIEDRICH ALEXANDER UNIVERSITY, Erlangen, Germany)

09:55 Crystallographic Structures Enable the Discovery of Selective 5-Ht1b Receptor Ligands through Virtual Screening

Dr David RODRIGUEZ DIAZ
(STOCKHOLM UNIVERSITY, Solna, Sweden)

Session 8.21 Neglected Tropical Diseases: Shaping Future Trends

08:30 Session Chair

Prof. Kelly CHIBALE
(UNIVERSITY OF CAPE TOWN, Cape Town, South Africa)

08:35 Update on Chemotherapy of Tropical Diseases Caused by Protozoan Parasites

Prof. Reto BRUN
(SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE, Basel, Switzerland)

09:15 Antimalarial Trioxolanes - Exploiting Peroxide Reduction For Parasite-Selective Drug Delivery

Prof. Adam RENSLO
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

09:35 Antimalarial Lead Discovery from phenotypic screening: Unraveling the Black Box

Dr Francisco-Javier GAMO
(GLAXOSMITHKLINE, Madrid, Spain)

09:55 Improving Physiochemical Properties of a Lapatinib-Based Lead Compound that Targets Trypanosoma Brucei

Prof. Jennifer WOODRING
(NORTHEASTERN UNIVERSITY, Boston, United States)

Session 8.22 New Therapies for Metabolic Disorders

08:30 Session Chair

Dr Jürgen MACK
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany)

08:35 Pharmaceutical Protein & Peptide Engineering: From Once Daily To Once Weekly GLP-1 Dosing

Dr Jesper LAU
(NOVO NORDISK, Maaloev, Denmark)

09:15 1,1'-Spiro-Substituted Hexahydrofuroquinoline Derivatives As Potent And Polar Cholesteryl Ester Transfer Protein (CETP) Inhibitors

Dr Thomas TRIESELNANN
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany)

09:35 Omarigliptin: A Once-weekly Oral Antidiabetic Agent

Dr Tesfaye BIFTU
(MERCK, Rahway, United States)

09:55 Discovery of GPR103 Ligands Demonstrating the Anorexigenic Effect in vivo of GPR103 Antagonism

Dr Anneli NORDQVIST
(ASTRAZENECA, BIOPHARMACEUTICALS R&D, Gothenburg, Sweden)

Programme Schedule

10:15 Exhibition & Coffee & Snacks

Session 9.23 Late Breaking News

10:45 Session Chair

Dr Laurence LAFANECHERE
(CNRS, Grenoble, France)

10:50 CHF-6001, an Inhaled PDE4 Inhibitor for Asthma and COPD: Synthesis, In Vitro and In Vivo Characterization

Dr Maurizio DELCANALE
(CHIESI, Parma, Italy)

11:10 The Discovery of AZD5069; a CXCR2 Antagonist In Phase II Clinical Trials for the Treatment of Asthma

Dr Rhona COX
(ASTRAZENECA, Mölndal, Sweden)

11:30 Discovery of BAY 85-8501, a Novel and Highly Potent Induced-Fit Binder of Human Neutrophil Elastase for Pulmonary Diseases

Dr Franz VON NUSSBAUM
(BAYER PHARMA, Berlin, Germany)

11:50 Discovery of TD-5959 (Batefenterol/GSK-961081): A First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and Beta-2 Agonist (MABA) for the Treatment of COPD

Dr Adam HUGHES
(THERAVANCE INC., South San Francisco, United States)

12:10 Identifying Selective Inhibitors of FGFR4 Kinase

Dr Kurt PIKE
(ASTRAZENECA, Cambridge, United Kingdom)

Session 9.24 Neurodegeneration: Deeper Understanding of Disease Biology and Emerging Therapeutic Options

10:45 Session Chair

Dr Andrew THOMAS
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

10:50 CaV1.3-Selective L-Type Calcium Channel Negative Allosteric Modulators. Novel Therapeutics to Slow the Progression of Parkinson's Disease

Prof. Rick SILVERMAN
(NORTHWESTERN UNIVERSITY, Evanston, United States)

11:30 Restoration of Muscle Mass and Lifespan in a Mouse Model of Spinal Muscular Atrophy by Molecular Correction of SMN2 Splicing Defect

Dr Hasane RATNI
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

11:50 Fragment-Based Discovery of BACE Inhibitors for Alzheimer's Disease

Dr Andrew STAMFORD
(MERCK RESEARCH LABORATORIES, Rahway, United States)

12:10 The Evolution of an in vivo Efficacious Bace1 Inhibitor

Dr Daniel OEHLRICH
(JANSSEN RESEARCH AND DEVELOPMENT, Beerse, Belgium)

Session 9.25 Translational Medicine: Case Studies with Biomarkers and PKPD Modeling

10:45 Session Chair

Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

10:50 Translational Modeling in Support to Discovery and Early Development

Dr Thierry LAVE
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

11:30 Non-Clinical Characterization And Clinical Translation Of LY2811376 And LY2886721

Dr Dustin James MERGOTT
(ELI LILLY, Indianapolis, United States)

11:50 A HTS Assay Predicting Both Passive Intestinal Absorption and Affinity Constant Towards Human Serum Albumin in a Two End-Point Measurement

Programme Schedule

Mr Alban BUJARD
(UNIVERSITY OF GENEVA, Geneva, Switzerland)

12:10 Biomarkers after Bacteriochlorin Based Photodynamic Therapy against Cancer

Dr Martyna KRZYKAWSKA-SERDA
(FACULTY OF BIOCHEMISTRY, BIOPHYSICS AND BIOTECHNOLOGY, JAGIELLONIAN UNIVERSITY, Krakow, Poland)

**12:30 Closing Lecture
Personalised Medicinal Systems Chemistry**

Prof. Hans WESTERHOFF
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

13:15 Closing Remarks, Poster Prizes and Welcome to EFMC-ISMIC 2016